[exclusive] the national drug volume purchase plan is coming! Remove the gray and completely block the gold sales! (attached)

In this joint procurement, a total of 31 varieties were purchased According to the requirements of the scheme, the declared varieties belong to the scope of the catalogue of purchased varieties, and meet one of the following requirements: - the original research drug and the generic drug quality and efficacy consistency evaluation reference preparation issued by the State Drug administration ——Generic drugs that pass the consistency evaluation of quality and efficacy of generic drugs by the State Drug Administration ——According to the announcement of the State Food and Drug Administration on the issuance of the work plan for the reform of the registration and classification of chemical drugs [2016 No 51], the generic drugs approved according to the new registration and classification of chemical drugs According to the criteria for determining the pre winning varieties, it will be divided into two parts: the pre winning varieties and the proposed winning varieties In the criteria for the determination of pre winning varieties, there are two situations: the one is determined according to the price and the other is determined according to the application conditions That is to say, if the number of enterprises with the same variety meeting the application conditions is ≥ 2, and the lowest price is only 1 enterprise, the application varieties of the enterprise are qualified for pre winning Those with the lowest price are selected as candidate enterprises, and those with the lowest price are selected when the selected enterprises cannot guarantee the supply If only one enterprise meets the application conditions, it will directly obtain the pre winning qualification; if the number of enterprises of the same variety meets the application conditions is more than or equal to two, when the lowest quotation is more than or equal to two enterprises, one enterprise will be determined to obtain the pre winning qualification according to the following rules and sequence: (1) the enterprises with more supply areas prior to the centralized purchase will have priority (including: Beijing Tianjin, Shanghai, Chongqing and Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, Xi'an) (2) In 2017, the enterprises with large sales volume of the main product specifications of the above 11 regions are preferred If there are multiple main product specifications, the sales volume shall be calculated in combination The above information is mainly based on the data submitted by each pilot area If we pass in the determination of the pre winning varieties, we will also face the game rules of the determination of the pre winning varieties, that is, the enterprises that have obtained the pre winning qualification and the declared varieties will enter into the negotiation and confirmation procedure (1) The number of enterprises meeting the application conditions ≥ 3 varieties: the price of the pre selected variety shen4 + 7 city drug centralized purchase document 11 meets the relevant requirements of this quotation, and after the confirmation of both parties, it is qualified for the proposed selection (2) Varieties with the number of qualified enterprises ≤ 2: ① those (no more than 7) with the highest price reduction rate of the pre selected varieties will be qualified for the proposed selection after being confirmed by both parties; ② other pre selected varieties: the lowest price reduction rate of negotiation will be determined by reference to the average reduction rate of the number of qualified enterprises ≥ 3 If the declared price meets the reduction requirements and an agreement is reached, the candidate will be eligible for the proposed election If the enterprise does not participate in or accept the negotiation, the variety will be treated as flow standard, which will affect the centralized purchase of the drugs involved in the pilot area (the decrease is based on the lowest purchase price at the end of 2017 in the pilot area) Before, when the 4 + 7 scheme was launched, there was a voice in the industry that through the national administrative force, a single enterprise was required to win the bid and enjoy 60% - 70% of the procurement volume of public hospitals in pilot cities Once the successful enterprises were short of supply for various reasons, it would cause huge social impact; the enterprises that lost the bid and the original research robbed 30% - 40% of the market volume, so there was too much competition Moreover, the price of the winning enterprise has been lowered too low, and the hospital is not necessarily willing to use it If the hospital is required to use it by administrative force, it only uses the specified quantity It is too difficult to expand the quantity rapidly after winning the bid, and the hospital will definitely take the initiative to use alternative varieties At the same time, even if the same variety passes the consistency evaluation, but the indications are similar and can be replaced too much From the prescription pen, hospital, business and enterprise, there must be a response method of "there are policies on the top and Countermeasures on the bottom" According to a foreign enterprise's market access essay, chronic diseases have drug compliance Once large-scale clinical substitution is realized, will adverse reactions collection after drug change be done well? At this point, he expressed doubts and confusion Wang Jun (pseudonym), a regional manager of a state-owned enterprise in Jiangsu Province, thinks it's lucky that he is not in the list of 33 varieties this time, so he will watch the price reduction trend first But after all, the national level joint procurement has been fully recognized by the high-level, strategic behavior, unstoppable On the whole, the target of "price for volume increase and gray area removal" is quite clear It can be expected that the gold carrying behavior that existed in the field of purchase and sale will be completely blocked through substantial price reduction Maybe this is an opportunity for "sales" to really start to change to "marketing" Although the living space of drug generation is small, professional chemistry The road of promotion will be opened up, and the compound sales talents who understand products, market and academy will occupy the mainstream The era of "drinking big wine and making big money" will be gone forever The new era of "purchasing with quantity" has come, and the market access function will be greatly strengthened It is the general trend for the country to gather resources Practitioners of knowledge must turn around in time and bid farewell to the golden age Otherwise, usher in, will not only be quantity and price fall together! Attachment: the first part of the original 4 + 7 city drug centralized procurement document invitation letter for 4 + 7 city drug centralized procurement (No.: gy-yd2018-1) (name of applicant): With the approval of the comprehensive Deepening Reform Commission of the Central Committee, the state has organized pilot drug centralized procurement, covering 11 cities (hereinafter referred to as 4 + 7 cities) including Beijing, Tianjin, Shanghai, Chongqing and Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu and Xi'an The joint procurement office (hereinafter referred to as "joint procurement") is composed of representatives appointed by the pilot area as the working organization to implement the centralized procurement on behalf of the public medical institutions in the pilot area The daily work and specific implementation are undertaken by the Shanghai Municipal Medical centralized bidding procurement affairs management office Now we are carrying out the centralized purchase of some drugs and related services for public medical institutions in the pilot area Please come to apply for them 1、 Purchase type and quantity According to the list of generic drugs approved by the State Food and Drug Administration for conformity assessment of quality and efficacy of generic drugs and the list of generic drugs approved by the State Food and drug administration according to the announcement of the State Food and Drug Administration on the issuance of the work plan for the reform of chemical drug registration and classification [2016 No 51], the following purchased products are determined through the joint procurement meeting and consultation with experts Category (specified specification) and agreed purchase volume: 2 Declaration qualification (1) declaration enterprise: refers to the domestic drug manufacturer providing drugs and accompanying services, and the domestic general agent of imported drugs is regarded as the manufacturer （2） Declared varieties: refer to the listed drugs that have obtained valid approval documents for domestic registration within the scope of the catalogue of purchased varieties （3） Declaration requirements: 1 The declaration enterprise promises that the annual production and marketing capacity of the declared varieties can meet the requirements of the procurement quantity 2 The declared varieties belong to the scope of the catalogue of purchased varieties, and meet one of the following requirements: 2.1 the original research drug and the generic drug quality and efficacy consistency evaluation reference preparation issued by the State Drug Administration 2.2 generic drugs that pass the consistency evaluation of quality and efficacy of generic drugs by the State Drug Administration 2.3 according to the announcement of the State Food and Drug Administration on the issuance of the work plan for the reform of the registration and classification of chemicals [2016 No 51], the generic drugs approved according to the new registration and classification of chemicals 3 The enterprise has the valid registration approval documents for the specified specifications of the purchased varieties When declaring varieties, each variety must include all the main product specifications produced by the enterprise 3、 Agreed purchase quantity and purchase execution instruction (I) agreed purchase quantity of drugs purchased in this centralized purchase shall be reported and determined by each pilot area （2） Centralized procurement results shall be uniformly implemented in each pilot area In the implementation cycle of centralized procurement results, medical institutions shall give priority to the use of the selected varieties of centralized procurement and ensure the completion of the agreed procurement volume （3） On the basis of giving priority to the use of the selected drugs in the centralized procurement, the medical institutions in each pilot area can purchase the non selected drugs with the same price in an appropriate amount according to the relevant provisions of the centralized procurement management in the region 4、 Purchase cycle this centralized purchase takes 12 months from the result execution date as a purchase cycle If the agreed purchase quantity is completed in advance within the purchase cycle, the excess part shall still be purchased according to the selected price until the expiration of the purchase cycle 5、 Please download the relevant documents on Shanghai Sunshine pharmaceutical purchasing website (www.smpaa CN) or on the website designated by the pilot area 6、 Time and place for submission of application materials (I) time: 8:30-10:00 (II) on Thursday, December 6, 2018 place: Multifunctional Hall on the first floor of building 6, No 1800 Tianshan Road (near Zhongshan West Road), Changning District, Shanghai (VII) time and place for disclosure of application information (I) time: 10:30 a.m on Thursday, December 6, 2018 （2） Venue: Multifunctional Hall on the first floor of building 6, no.1800 Tianshan Road (near Zhongshan West Road), Changning District, Shanghai VIII Negotiation confirmation time and venue (I) time: Thursday, December 6, 2018 at two o'clock (II) place: conference room on the second floor of building 6, no.1800 Tianshan Road (near Zhongshan West Road), Changning District, Shanghai IX contact information （1） Tel: 021-31773206, 021-31773278 (II) fax: 021-31773270 X other (I) joint procurement has carried out fair competition review by means of self review The documents related to this centralized procurement do not have the effect of excluding and restricting competition （2） According to the relevant requirements of the pilot work, each pilot area issues supplementary documents on purchase and sale contracts, drug distribution, quality testing, price adjustment of unselected varieties, medical insurance payment standards, etc The second part is the notice to the declaration enterprise A The parties involved in the centralized procurement 1 The declaration enterprise 1 The declaration enterprise shall have the following conditions to participate in the centralized procurement: (1) have the ability to perform the contract; (2) have no serious illegal records in the pharmaceutical production activities within two years before participating in the centralized procurement activity; (3) Must be responsible for the quality of drugs, timely and sufficient production according to the requirements of joint procurement, and send drugs to distribution enterprises 1.2 the declaration enterprise shall prepare the declaration materials in accordance with the requirements of the procurement documents, and the declaration materials shall respond to the requirements and conditions of the procurement documents 2 Other requirements 2.1 if the applicant obviously does not meet all the requirements specified in the application qualification, or is suspected of providing substantiating supporting materials, once confirmed, the joint procurement will not accept the application; if the circumstances are serious, the participation qualification of all the drugs produced by the enterprise in the drug procurement activities in each pilot area within the procurement cycle will be cancelled 2.2 in the two years before participating in this centralized procurement activity, the drugs declared by the enterprise do not have the unqualified situation in the quality inspection of the drug regulatory departments at or above the provincial level (among which, generic drugs refer to the unqualified situation after being produced and listed according to the requirements of the conformity evaluation of the quality and efficacy of generic drugs by the State Drug Administration) 2.3 in principle, the drugs supplied according to the purchased varieties should be commonly used in clinical packaging 2.4 joint procurement can investigate the drug production and quality of the selected enterprise according to the work needs (the investigation form shall be determined according to the actual situation), and the selected enterprise shall actively cooperate 2.5 after the applicant is selected, the purchase and sale contract shall be signed according to the requirements of the pilot area 2.6 in case of any national policy adjustment or force majeure during the performance of the contract, the selected drugs will directly